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Abstract 
Background: Myelodysplastic syndrome (MDS) is an important precancerous disease leading to blood 
malignancies. Prompt diagnosis and treatment would result in better outcome in patients. Purpose of the study 
was to determine the effect of Epoetin Alfa and Sodium Valproate in patients with MDS. 
Materials and Methods: In this interventional quasi-experimental study, 50 consecutive patients with MDS from 
Taleghani Hospital (Tehran, Iran) in 2016-2017 were enrolled. They underwent treatment for eight months with 
10000 units per month from Epoetin Alfa plus 200 mg TDS from Sodium Valproate. The hematological response 
was determined according to the hemoglobin, platelet, and neutrophil. 
Results: Hematological response was present in 68%. The packed cell treatment were decreased significantly 
(P=0.040) and 56% of patients had no receipt of packed cells after treatment. 
Conclusion: It is concluded that Epoetin Alfa plus Sodium Valproate was effective in treatment of patients with 
Myelodysplastic syndrome and use of this combination therapy is recommended. 
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Introduction 
Myelodysplastic syndrome (MDS) includes a group of 
diseases with dysplastic alterations in myeloid, 
erythroid, and megacaryocyte subtypes1 leading to 
cytopenia in some blood cells resulting in anemia and 
fatigue, neutropenia and infection, thrombocytopenia 
and bleeding1,2. Nearly fifty percent of cases may 
change to acute myeloid leukemia1-3. Erythropoietic 
stimulating agents (ESA) are usually used for 
treatment of MDS cases4,5 have shown positive 
efficacy in comparison with supportive cases6. 
Usually these therapeutics have higher doses versus 
epoietin alfa ranging from 40000 to 80000 units 
weekly7,8. Low-dose ESA has lower response rate9. 
Some studies have used low dose epoietin alfa leading 
to lack of response and cotroverssies10.  
Valproic acid is a small chain fatty acid using as anti-
convulsant for years and is effective on growth and 
differentiation of malignant cells11. Different studies 
have shown various results for valproic acid and in 
some studies, no effect on MDS and AML is seen12. 
The recent study about epoetin alfa found significant 
effect with high-dose13. In addition, valproic acid has 
shown up to forty percent efficacy in MDS cases and 
should be used simultaneously with other 
therapeutics11. Regarding these controversies, in this 
study the efficacy of Epoetin Alfa and Sodium 
Valproate combination in MDS patients was assessed. 
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Methods 
In this interventional quasi-experimental study, 50 
consecutive patients with MDS in Taleghani hospital 
(Tehran, Iran) in 2016-2017 were enrolled. Inclusion 
criteria were willing to incorporation in the study, easy 
to follow-up and blood-product dependent MDS. 
Exclusion criteria were previous successful 
treatments, death, and study termination. Local ethical 
committee approved the study and informed consent 
form received from all patients. Helsinki declaration 
was respected across the study. 
They underwent treatment for eight months with 
10000 units per month from Epoetin Alfa plus 200 mg 
TDS from Sodium Valproate. Valproic acid for 
treatment of seizure leads to inhibition of enzymatic 
activity and HDAC inhibition14,15. Duration of 
treatment was eight months including both drugs. The 
hematological response was determined according to 
the hemoglobin, platelet, and neutrophil. In addition, 
transfusion times and volume was recorded from the 
first week. 
Data analysis was done among patients with SPSS 
version 13.0 software. The used tests were 
Independent-Sample-T, Fisher, and Chi-Square and 
the P value less than 0.05 were considered significant. 
Results 
In this study, 32 out of 50 patients (64%) were male. 
The mean (standard deviation) age was 65.3 (7.7) 
ranging from 53 to 84 years. The mean (standard 
deviation) duration of disease was 3.03 (2.4) ranging 
from 1 to 12 years. MDS subtype was with multilinage 
and unilinage in 38 and 62 percent, respectively. 
Hematological response rate was 68%. Also as shown 
in Figure 1, the used pack cells were reduced after 
treatment with significant difference (P=0.040) and no 
pack cell use seen in 56% of patients after treatment. As 
shown in Figure 2 and Figure 3, the hematological 
responding cases had higher mean age (P=0.019) and 
lower duration of disease (P=0.037). However, the age 
and MDS subtype had no effect on therapeutic response 
among the patients (P > 0.05). 
Discussion 
In this study the efficacy of Alfa epoietin plus valproic 
acid was assessed to attain definite results about 
efficacy of these insurance-accepted therapeutics for 
MDS cases and also decrease the controversies. We 
found response rate of 68 percent and significant 
reduction in pack cell use. In a study among 
transfusion-dependent MDS cases, ESA agents 
similarly had good efficacy13. In a study among 23 
cases under treatment with valproic acid, the response 
rate was 44 percent this lower than our study but in 
congruence with our study and other studies16,17. A 
review study by Hellström-Lindberg et al18 reported 
median response duration of 2 to 3 years. However, in 
 
 
Figure 1. Pack cell use before and after treatment. 
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our study longer follow-up was impossible. 
Toma et al19 assessed 131 patients reported efficacy of 
23 percent for erythropoietin alone rising to 39 percent 
in combination with other agents without significant 
increase in drug adverse effects as well as our study. 
Park et al20, 21 assessed 1147 MDS patients and found 
efficacy and response of 61.5% with low response rate 
seen by second line treatment such as sodium 
valproate which was contrary to our study. Ornestein 
et al22 declaimed good efficacy of combination therapy 
that was also approved in our study. In addition, Poloni 
et al23 reported a case of MDS female patient with 
successful treatment outcomes with valproic acid and 
showed no recurrence of malignancy transformation 
that is similar to our study. Terpos et al24 in the Italian 
co-operative study prolong administration of 
erythropoietin is conduce to long lasting erythroid RR 
in MDS patients that similar to our study. 
 
 




Figure 3. Mean duration of disease according to hematological response. 
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According to our study, the average age of those who 
responded to treatment was higher, also, the mean 
duration of illness was higher in those who responded 
to treatment and there was no difference between sex 
and subtype of the disease. 
Conclusion 
It is concluded that Epoetin Alfa plus Sodium 
Valproate is effective in treatment of patients with 
Myelodysplastic Syndrome and use of this 
combination therapy is recommended. However 
further studies with larger sample population and 
multi-center sampling is required to attain results that 
are more definite and better therapeutic decision 
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